# MedPacto

Source: https://onco.cc/companies/medpacto/  
OnCo record `medpacto` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MedPacto is a South Korean biotech whose oral TGF-beta receptor inhibitor vactosertib is being tested with chemotherapy and checkpoint inhibitors in colorectal, stomach and bone-marrow cancers.

## Summary

MedPacto, listed on KOSDAQ, develops vactosertib (TEW-7197), an oral inhibitor of the TGF-beta type 1 receptor kinase ALK5 that aims to relieve the immunosuppressive and fibrotic effects of TGF-beta in the tumour microenvironment. Vactosertib is in a phase 2/3 trial with FOLFIRI and bevacizumab in second-line metastatic colorectal cancer and has been studied with pembrolizumab in colorectal and gastric cancer, with pomalidomide in multiple myeloma and in osteosarcoma.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: MedPacto Inc.; 메드팩토; KOSDAQ:235980
- Tags: drug-maker
- HQ: Seoul
- Type: biotech
- Website: https://www.medpacto.com/
- Ticker: KOSDAQ:235980

## Sources

- Official website: https://www.medpacto.com/

## Connected records

- drugs: [Vactosertib](https://onco.cc/drugs/vactosertib/)

---
JSON: https://onco.cc/api/v1/entities/medpacto.json